CN110198943A - 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 - Google Patents
作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 Download PDFInfo
- Publication number
- CN110198943A CN110198943A CN201880008008.9A CN201880008008A CN110198943A CN 110198943 A CN110198943 A CN 110198943A CN 201880008008 A CN201880008008 A CN 201880008008A CN 110198943 A CN110198943 A CN 110198943A
- Authority
- CN
- China
- Prior art keywords
- compound
- added
- synthesis
- solution
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
本发明公开了一类具有Wee1的抑制作用的1,2‑二氢‑3H‑吡唑[3,4‑d]嘧啶‑3‑酮类化合物,并包含这些化合物在治疗各类肿瘤方面的应用。
Description
PCT国内申请,说明书已公开。
Claims (22)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710058856 | 2017-01-23 | ||
CN2017100588568 | 2017-01-23 | ||
CN201711376769 | 2017-12-19 | ||
CN2017113767693 | 2017-12-19 | ||
PCT/CN2018/073360 WO2018133829A1 (zh) | 2017-01-23 | 2018-01-19 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110198943A true CN110198943A (zh) | 2019-09-03 |
CN110198943B CN110198943B (zh) | 2021-04-16 |
Family
ID=62907769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880008008.9A Active CN110198943B (zh) | 2017-01-23 | 2018-01-19 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10954253B2 (zh) |
EP (1) | EP3572413B1 (zh) |
JP (1) | JP6717457B2 (zh) |
CN (1) | CN110198943B (zh) |
ES (1) | ES2902050T3 (zh) |
WO (1) | WO2018133829A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114591334A (zh) * | 2020-12-04 | 2022-06-07 | 山东轩竹医药科技有限公司 | 二氢吡唑并嘧啶酮衍生物 |
WO2024011883A1 (zh) * | 2022-07-13 | 2024-01-18 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
US10807994B2 (en) | 2017-10-09 | 2020-10-20 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
AU2019227823A1 (en) * | 2018-02-28 | 2020-08-06 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
EP3762385A4 (en) | 2018-03-09 | 2021-11-24 | Recurium IP Holdings, LLC | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDINE-3-ONE |
KR20210141659A (ko) | 2019-03-22 | 2021-11-23 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | Wee1 억제제 및 이의 제조 및 용도 |
JP2022526831A (ja) | 2019-04-09 | 2022-05-26 | ニューベイション・バイオ・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
WO2020259703A1 (zh) | 2019-06-28 | 2020-12-30 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
CN112142748B (zh) | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
EP4169919A1 (en) * | 2020-06-17 | 2023-04-26 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Pyrazolo[3,4-d]pyrimidine-3-ketone derivative as wee-1 inhibitor |
CN118176195A (zh) * | 2021-11-01 | 2024-06-11 | 正大天晴药业集团股份有限公司 | 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途 |
CN116462687A (zh) | 2022-01-18 | 2023-07-21 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
CN115521309A (zh) * | 2022-09-16 | 2022-12-27 | 思科(深圳)药物研发有限公司 | 一种依鲁奥克杂质及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101432284A (zh) * | 2006-04-27 | 2009-05-13 | 万有制药株式会社 | 二氢吡唑并嘧啶酮衍生物 |
EP2213673A4 (en) * | 2007-10-23 | 2011-09-07 | Msd Kk | PYRIDONE-SUBSTITUTED DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE |
CN105209463A (zh) * | 2013-04-11 | 2015-12-30 | 阿尔麦克探索有限公司 | 2-氨基吡啶并[4,3-d]嘧啶-5-酮衍生物及其作为Wee-1抑制剂的用途 |
CN105829315A (zh) * | 2013-12-19 | 2016-08-03 | 阿尔麦克探索有限公司 | 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198281B2 (en) | 2007-04-25 | 2012-06-12 | Merck Sharp & Dohme Corp. | Crystalline forms of dihydropyrazolopyrimidinone |
PT2477628E (pt) | 2009-09-15 | 2014-11-25 | Merck Sharp & Dohme | Preparação de formas de hemihidrato cristalino de dihidropirazolopirimidinona |
TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
WO2013013031A1 (en) | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
EP2755482B1 (en) * | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combination of mk-1775 and mk-8776 for treating cancer |
JP2014530867A (ja) | 2011-10-20 | 2014-11-20 | アッヴィ・インコーポレイテッド | キナーゼのピリドピリミジノン阻害剤 |
CA2864142A1 (en) | 2012-02-23 | 2013-08-29 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
CN104130265B (zh) * | 2014-04-29 | 2017-01-25 | 苏州景泓生物技术有限公司 | 一种含有螺环或桥环的嘧啶类化合物 |
ES2714576T3 (es) * | 2014-07-04 | 2019-05-29 | Qilu Pharmaceutical Co Ltd | Oxido de arilfósforo y sulfuro de arilfósforo espirocíclicos |
EP3368538B1 (en) | 2015-11-01 | 2021-09-01 | The Regents of The University of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
-
2018
- 2018-01-19 WO PCT/CN2018/073360 patent/WO2018133829A1/zh unknown
- 2018-01-19 EP EP18741681.3A patent/EP3572413B1/en active Active
- 2018-01-19 CN CN201880008008.9A patent/CN110198943B/zh active Active
- 2018-01-19 ES ES18741681T patent/ES2902050T3/es active Active
- 2018-01-19 JP JP2019539902A patent/JP6717457B2/ja active Active
- 2018-01-19 US US16/479,936 patent/US10954253B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101432284A (zh) * | 2006-04-27 | 2009-05-13 | 万有制药株式会社 | 二氢吡唑并嘧啶酮衍生物 |
EP2213673A4 (en) * | 2007-10-23 | 2011-09-07 | Msd Kk | PYRIDONE-SUBSTITUTED DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE |
CN105209463A (zh) * | 2013-04-11 | 2015-12-30 | 阿尔麦克探索有限公司 | 2-氨基吡啶并[4,3-d]嘧啶-5-酮衍生物及其作为Wee-1抑制剂的用途 |
CN105829315A (zh) * | 2013-12-19 | 2016-08-03 | 阿尔麦克探索有限公司 | 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114591334A (zh) * | 2020-12-04 | 2022-06-07 | 山东轩竹医药科技有限公司 | 二氢吡唑并嘧啶酮衍生物 |
CN114591334B (zh) * | 2020-12-04 | 2023-10-20 | 山东轩竹医药科技有限公司 | 二氢吡唑并嘧啶酮衍生物 |
WO2024011883A1 (zh) * | 2022-07-13 | 2024-01-18 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
Also Published As
Publication number | Publication date |
---|---|
JP6717457B2 (ja) | 2020-07-01 |
US20200017528A1 (en) | 2020-01-16 |
JP2020510630A (ja) | 2020-04-09 |
WO2018133829A1 (zh) | 2018-07-26 |
EP3572413A1 (en) | 2019-11-27 |
EP3572413B1 (en) | 2021-11-03 |
ES2902050T3 (es) | 2022-03-24 |
CN110198943B (zh) | 2021-04-16 |
US10954253B2 (en) | 2021-03-23 |
EP3572413A4 (en) | 2020-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110198943A (zh) | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 | |
JP2022505987A (ja) | Tyk2阻害剤およびその使用 | |
CN109071538A (zh) | 作为ask1抑制剂的吡啶衍生物及其制备方法和应用 | |
AU2013213603B2 (en) | PDE9 inhibitors with imidazo triazinone backbone | |
CN108349977A (zh) | Jak抑制剂 | |
TW201823249A (zh) | Menin-mll相互作用之稠合二環抑制劑 | |
CN107531711A (zh) | Janus激酶抑制剂 | |
CN110418789A (zh) | 作为治疗剂的N-环烷基/杂环烷基-4-(咪唑并[1,2-a]吡啶)嘧啶-2-胺的衍生物 | |
CN105228997A (zh) | Carm1抑制剂及其用途 | |
TW202216686A (zh) | 藉由使egfr抑制劑與e3連接酶配位體結合來降解(egfr)以及使用方法 | |
CN109790159A (zh) | 抗流感病毒嘧啶衍生物 | |
CN104540830A (zh) | 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂 | |
CA2961607A1 (en) | Mk2 inhibitors and uses thereof | |
CN107531695A (zh) | Jak抑制剂 | |
CN111344290A (zh) | 作为Wee1抑制剂的大环类化合物及其应用 | |
CN107108579A (zh) | 作为adamts抑制剂用于治疗骨关节炎的5‑[(哌嗪‑1‑基)‑3‑氧代‑丙基]‑咪唑烷‑2,4‑二酮衍生物 | |
CN110088101A (zh) | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 | |
WO2007040166A1 (ja) | 新規な縮合ピロール誘導体 | |
CN111683928B (zh) | 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物 | |
CN109661395A (zh) | Pde4抑制剂 | |
CN110325517A (zh) | 螺环类化合物及其应用 | |
CN105085525B (zh) | 作为rho激酶抑制剂的异喹啉磺酰衍生物 | |
AU2022202463A1 (en) | Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof | |
JP2022523477A (ja) | ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物 | |
CA3201540A1 (en) | Aromatic heterocyclic compound, pharmaceutical composition and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220629 Address after: 214000 room 315, No. 88, Meishan Meiliang Road, Binhu District, Wuxi City, Jiangsu Province Patentee after: Wuxi Zhikang Hongyi Biotechnology Co.,Ltd. Address before: 050035 Innovation Building, 315 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province, 3rd Floor Patentee before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd. |